\
&
Contact us
\
&
Contact us
Published on | 2 weeks ago
ProgrammesEIT Health’s Innovation Uptake Call focuses on mature digital, data-driven and AI-powered solutions and seeks to support the last steps towards commercialisation.
Applicants must apply as a consortium of at least two independent legal entities from different countries. The consortium must include partners from at least two sides of the Knowledge Triangle: industry, research and education. Projects must be led by a commercialising entity, either an SME or another industry player, responsible for bringing the solution to market.
The maximum funding per project is €650,000 (total budget €5,2 million) and the grant may cover up to 50% of total project costs, so co-funding is required. Funded activities may include commercialisation pilots in real-world healthcare settings, usability testing and market adaptation, go-to-market strategy, business model validation and health economics analysis.
The call was opened on 24 June 2026 and will close on 16 September 2026. An information session is scheduled for 15 July 2026 from 12:30 to 13:30 CET, and an open Q&A session for 1 September 2026 at 11:00 CET. More information is available on the website of the call.
Background: The European institute of Innovation and Technology (EIT) stands at the crossroad of business creation, innovation and education. It consists of ten knowledge and innovation communities. The overall objective is to transform promising innovations into succesful companies.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space EIT Deployment: Best use of technologies
The Co-Creation Accelerator is a programme run by 28DIGITAL (formerly EIT Digital). It brings together start-ups and industry partners to co-develop solutions to real-world challenges, with a focus on: Validating core technology (TRL 4-5 and above) Strengthening problem-solution fit Reducing technical and market uncertainty Building a cle... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
